• Connect Biopharma outlined development plans for rademikibart, an anti-IL-4Rα monoclonal antibody with global rights outside greater China.
• Phase 2 studies in acute COPD and asthma exacerbations started in 2Q2025, with topline data expected in mid-2026; study is being run by Simcere at no cost to Connect.
• Simcere filed an NDA in China for atopic dermatitis in July 2025.
• U.S. FDA agreed rademikibart is ready to move into Phase 3 for chronic treatment of asthma and atopic dermatitis, based on results from completed studies.
• Presentation highlighted clinical and preclinical comparisons versus dupilumab, including a reported reduction in eosinophils in asthma patients and potential for less frequent dosing in atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.